Search

Viking Therapeutics Inc

Open

SectorGezondheidszorg

34.36 2.66

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

32.61

Max

34.95

Belangrijke statistieken

By Trading Economics

Inkomsten

30M

-128M

EPS

-1.1

Werknemers

65

EBITDA

30M

-128M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+170.84% upside

Dividenden

By Acuity

Volgende Winsten

21 okt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-126M

3.9B

Vorige openingsprijs

31.7

Vorige sluitingsprijs

34.36

Nieuwssentiment

By Acuity

50%

50%

150 / 340 Rangschikking in Healthcare

Viking Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 aug 2026, 19:56 UTC

Social Media

Viking Therapeutics Inc shares are lower today, continuing a decline since Friday. Social media discussions highlight anticipation for upcoming data before Labor Day.

20 aug 2026, 20:06 UTC

Macro Event
Social Media

Viking Therapeutics Inc shares are lower, impacted by labor market data and heightened volatility, despite social media discussions suggesting potential recovery from a clinical trial.

19 aug 2026, 23:16 UTC

Viking Therapeutics Inc shares are higher in after-market hours, reflecting a gain since Wednesday's close and remaining above the 20-day moving average.

18 aug 2026, 19:16 UTC

Viking Therapeutics Inc shares are lower today, with no specific news driving the decline amid rising U.S. Treasury yields affecting the biotechnology sector.

17 aug 2026, 23:06 UTC

Viking Therapeutics Inc shares are higher in after-market trading, reflecting unusual strength. No specific company news was identified to explain the price movement.

14 aug 2026, 23:06 UTC

Viking Therapeutics Inc shares are lower in after-market hours, trading at the lower end of their one-month range and below the 20-day moving average.

13 aug 2026, 23:16 UTC

Viking Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock is near its one-month low.

12 aug 2026, 23:26 UTC

Viking Therapeutics Inc is trading lower in after-market hours, reflecting notable weakness with no specific news identified to explain the decline.

7 aug 2026, 19:36 UTC

Social Media

Viking Therapeutics is rising amid broader market gains and anticipation of VK2809 trial results, with analysts noting potential for improved market position.

6 aug 2026, 23:16 UTC

Social Media

Viking Therapeutics Inc gains in after-market hours amid discussions on pharmacokinetic modeling and anticipated VKTX maintenance readout results.

5 aug 2026, 22:51 UTC

Viking Therapeutics Inc. shares are lower in after-market hours, continuing a decline from Wednesday's close amid unusual volatility and trading below the 20-day moving average.

4 aug 2026, 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3 aug 2026, 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31 jul 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30 jul 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29 jul 2026, 23:21 UTC

Social Media
News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28 jul 2026, 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27 jul 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

25 jul 2026, 00:01 UTC

Viking Therapeutics Inc shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down. No specific news was identified.

24 jul 2026, 21:01 UTC

Viking Therapeutics Inc. is higher in after-market trading, reversing recent losses despite no specific news driving the price movement.

23 jul 2026, 23:46 UTC

Event

Viking Therapeutics shares are higher in after-market trading ahead of Q2 earnings, with estimated EPS of -$1.21, up from -$0.58.

22 jul 2026, 23:36 UTC

Viking Therapeutics Inc. shares showed little change during after-market hours, trading within a narrow range and settling near unchanged levels.

Peer Vergelijking

Prijswijziging

Viking Therapeutics Inc Prognose

Koersdoel

By TipRanks

170.84% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 90 USD  170.84%

Hoogste 114 USD

Laagste 65 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Viking Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Sentiment

By Acuity

150 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
help-icon Live chat